StockData
Context Therapeutics Inc. logo

Context Therapeutics Inc. (CNTX) stock

CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.18−0.02 (-8.69%)

Close on Nov 13, 2026Market cap $16.61MP/E –Yield –

Earnings

Context Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Context Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2022ended Dec 31, 2022Mar 22, 2023during market hours–––Release
Q4 FY2021ended Dec 31, 2021Mar 23, 2022during market hours–––Release
Q3 FY2021ended Sep 30, 2021Dec 2, 2021during market hours–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Context Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Context Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Context Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
    Update
  2. November 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
    Update
  3. August 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
    Update
  4. June 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
    Update
  5. Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
    Update
  6. June 15, 2026 Phase 1 Interim Results CTIM-76: A Novel CLDN6 x CD3 TCE
    Update
  7. Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
    Update
  8. Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
    Update
  9. March 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
    Update
  10. January 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
    Update
  11. November 2025 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
    Update
  12. Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
    Update
  13. June 2025 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
    Update
  14. Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
    Update
  15. Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
    Update

See a number that looks wrong?